ASP Isotopes Inc. (NASDAQ:ASPI) Sees Large Increase in Short Interest

ASP Isotopes Inc. (NASDAQ:ASPI) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 6,770,000 shares, a growth of 13.8% from the December 15th total of 5,950,000 shares. Based on an average daily trading volume, of 5,090,000 shares, the days-to-cover ratio is currently 1.3 days. Currently, 14.6% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on ASPI shares. Canaccord Genuity Group restated a “buy” rating and set a $4.50 price objective on shares of ASP Isotopes in a research report on Friday, October 18th. Canaccord Genuity Group started coverage on ASP Isotopes in a research report on Friday, October 4th. They issued a “buy” rating and a $4.50 target price for the company.

ASP Isotopes Stock Performance

NASDAQ ASPI traded up $0.52 on Friday, reaching $5.66. The stock had a trading volume of 2,735,525 shares, compared to its average volume of 2,112,098. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.54 and a current ratio of 7.55. ASP Isotopes has a 1 year low of $1.86 and a 1 year high of $9.33. The business has a 50 day moving average price of $5.51 and a 200 day moving average price of $4.08.

Institutional Investors Weigh In On ASP Isotopes

Several large investors have recently made changes to their positions in ASPI. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in ASP Isotopes in the third quarter valued at approximately $6,249,000. Telemark Asset Management LLC bought a new position in shares of ASP Isotopes during the 3rd quarter valued at $4,726,000. Philadelphia Financial Management of San Francisco LLC lifted its stake in shares of ASP Isotopes by 158.3% in the 3rd quarter. Philadelphia Financial Management of San Francisco LLC now owns 991,863 shares of the company’s stock valued at $2,757,000 after purchasing an additional 607,893 shares during the last quarter. Marshall Wace LLP boosted its holdings in ASP Isotopes by 389.6% in the second quarter. Marshall Wace LLP now owns 545,072 shares of the company’s stock worth $1,668,000 after purchasing an additional 433,734 shares in the last quarter. Finally, GSA Capital Partners LLP increased its position in ASP Isotopes by 96.0% during the third quarter. GSA Capital Partners LLP now owns 770,989 shares of the company’s stock worth $2,143,000 after buying an additional 377,721 shares during the last quarter. Institutional investors own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.